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High-mobility group box-1 (HMGB-1) is expressed in almost 
all cells, and its dysregulated expression correlates with 
inflammatory diseases, ischemia, and cancer. Some of these 
conditions accompany HMGB-1-mediated abnormal angio-
genesis. Thus far, the mechanism of HMGB-1-induced 
angiogenesis remains largely unknown. In this study, we 
performed time-dependent DNA microarray analysis of 
endothelial cells (ECs) after HMGB-1 or VEGF treatment. The 
pathway analysis of each gene set upregulated by HMGB-1 or 
VEGF showed that most HMGB-1-induced angiogenic 
pathways were also activated by VEGF, although the activation 
time and gene sets belonging to the pathways differed. In 
addition, HMGB-1 upregulated some VEGFR signaling-related 
angiogenic factors including EGR1 and, importantly, novel 
angiogenic factors, such as ABL2, CEACAM1, KIT, and VIPR1, 
which are reported to independently promote angiogenesis 
under physiological and pathological conditions. Our findings 
suggest that HMGB-1 independently induces angiogenesis by 
activating HMGB-1-specific angiogenic factors and also 
functions as an accelerator for VEGF-mediated conventional 
angiogenesis. [BMB Reports 2017; 50(11): 590-595]
INTRODUCTION
The highly conserved protein high-mobility group box-1 
(HMGB-1) plays various roles according to cellular localiza-
tion and is expressed in almost all mammalian cells (1, 2). 
Secreted HMGB-1 functions as an immune cell-associated 
cytokine that induces systemic inflammation, cell proliferation, 
signal transduction, and activation of endothelial cells (ECs) 
(3). Secreted HMGB-1 activates downstream signaling pathways 
(CDC42/Rac, MAPK, NF-B, and PI3K-Akt) by binding to 
several known receptors, such as the receptor for advanced 
glycation end products (RAGE) and the Toll-like receptors 
TLR-2, TLR-4, and TLR-9 (4-7).
The pathogenic functions of HMGB-1 have been documen-
ted in a wide range of diseases such as neurodegeneration, 
aging, ischemia, and cancers (8-10). In particular, HMGB-1 
overexpression is now considered a hallmark of various types 
of cancers including colon, breast, and lung cancer and 
hepatocellular carcinoma, and its expression correlates with 
invasion, metastasis, and poor prognosis (11). Therefore, 
HMGB-1-targeted cancer therapeutic strategies using siRNA 
and antibodies have been developed and applied to in vitro 
and in vivo disease models (12, 13). HMGB-1 inhibition by 
these agents potently suppresses the progression of cancers 
through the perturbations of migration, proliferation, and 
angiogenesis (7, 14). The inhibition of angiogenesis is parti-
cularly important in advanced cancers because angiogenesis is 
a crucial step for the acquisition of malignant properties such 
as metastasis and invasion (15). While HMGB-1-mediated 
angiogenesis is disturbed by siRNA-mediated downregulation 
of RAGE or by HMGB-1 neutralizing antibody (16, 17), the 
mechanisms of HMGB-1-mediated angiogenesis are not fully 
understood in terms of the transcriptomic changes caused by 
exogenous HMGB-1 stimulation. Moreover, the differences 
between HMGB-1-mediated angiogenesis and conventional 
VEGF-mediated angiogenesis are essentially unknown. 
In this study, we aimed to characterize the angiogenic 
pathways and genes activated in ECs treated with HMGB-1 or 
VEGF at various time points and how they contribute to 
angiogenesis. We found that HMGB-1 as well as VEGF 
significantly induced proangiogenic features in ECs, accom-
panying time-dependent activation of angiogenic pathways. 
HMGB-1 treatment also resulted in HMGB-1-specific upregula-
tion and VEGF-like upregulation of oncogenic and angiogenic 
genes. Our findings indicate that HMGB-1 can function as a 
potent angiogenic signal both independently and synergis-
tically in combination with other angiogenic signals. 
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Fig. 1. HMGB-1 and VEGF stimulate proangiogenic features in 
ECs. (A) Proliferation assay. ECs were counted after 48 hours of 
HMGB-1 or VEGF treatment. (B) Invasion assay. Migrated ECs 
were stained and counted after 18 hours of treatment with 
HMGB-1 or VEGF. (C and D) Wound healing assay. Relative 
wound healing rates were measured in ECs after wound creation 
and 24 hours of treatment with HMGB-1 or VEGF. (E and F) 
Tube formation assay. The relative number of tubes and tube 
length were measured manually after ECs were incubated on 
Martrigel with HMGB-1 or VEGF for 2, 6, and 12 hours.
Fig. 2. HMGB-1 induces angiogenic pathways via genes specifi-
cally activated by HMGB-1 and those activated by both HMGB-1 
and VEGF. (A) Analysis pipeline of time-dependent gene ex-
pression microarray performed in ECs treated with HMGB-1 or 
VEGF. (B) K-means cluster analysis in ECs treated with HMGB-1 
or VEGF for various periods of time. (C) Ontology analysis of 
genes upregulated by HGMB-1 or VEGF during at least two time 
points. (D) Time-dependent expression patterns of genes specifically
upregulated by HMGB-1 (n = 59) and those upregulated by both 
HMGB-1 and VEGF (n = 24). 
RESULTS
HMGB-1 treatment confers proangiogenic features on ECs 
Given the expected roles of HMGB-1 in angiogenesis, we first 
tested whether exogenous HMGB-1 treatment stimulated 
proangiogenic features in ECs by evaluating proliferation, 
migration, wound healing, and tube formation after HMGB-1 
treatment in a time-dependent manner. ECs were isolated from 
human placental microvessels and validated by analyzing 
CD31 expression using fluorescence-activated cell sorting 
(FACS; data not shown). ECs were counted after 48 hours of 
HMGB-1 or VEGF treatment, and relative proliferation was 
measured. HMGB-1 treatment induced an approximately 
twofold increase in EC proliferation compared to that of VEGF 
treatment (Fig. 1A). The migration assay also showed that 
HMGB-1 treatment increased migrated EC numbers 2.5-fold 
(Fig. 1B). The wound healing assay to further evaluate both 
migration and cell–cell interaction showed that wound healing 
was significantly promoted by HMGB-1 treatment (Fig. 1C and 
D) and that HMGB-1-treated ECs were more likely to form 
capillary-like structures (Fig. 1E and F). Although VEGF- 
mediated proangiogenic activation of ECs is well known, we 
further confirmed that exogenous VEGF treatment strongly 
induced the proangiogenic features of ECs in our system (Fig. 
1A-F). 
Microarray profiling of gene expression in ECs activated by 
HMGB-1 or VEGF 
We performed gene expression microarray analysis to clarify 
the molecular mechanism of HMGB-1-induced EC activation 
at the gene expression level. ECs were treated with HMGB-1 
or VEGF at various time points to investigate time-dependent 
gene expression changes. RNAs were extracted from ECs 
harvested at early time points (20 and 45 minutes after 
HMGB-1 or VEGF treatment) and late time points (2, 6, and 12 
hours after HMGB-1 or VEGF treatment), and gene expression 
microarray profiling was performed. By pre-processing the raw 
data, we obtained 19,389 and 19,335 probes in HMGB-1- 
treated and VEGF-treated samples, respectively. Further 
selection of probes that showed more than 1.5-fold up- or 
downregulation resulted in 507 probes in HMGB-1-treated 
samples and 1,212 probes in VEGF-treated samples (Fig. 2A). 
Selected probes were mapped to official genes and K-means, 
and hierarchical clustering was performed using the list of 
obtained genes. K-means cluster analysis showed that gene 
expression was distinctively altered in a time-dependent 
manner in ECs treated with HMGB-1 compared to that in ECs 
treated with VEGF. Gene expression patterns changed 
dramatically between 45 minutes and 2 hours after HMGB-1 
treatment, while VEGF treatment induced more gradual gene 
expression changes (Fig. 2B). To validate our microarray data, 
eight genes that showed distinct expression levels at each time 
point after HMGB-1 or VEGF treatment were selected (CCL2, 
CCND2, EPHB1, PCDH12, VASH1, TMEM140, CD34, and 
EGR1), and qRT-PCR was performed in another set of EC 
samples treated with HMGB-1 or VEGF in the same manner as 
in the microarray analysis. To accurately compare our 
microarray data with qRT-PCR data, expression intensities of 
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the eight genes obtained from our microarray data were 
normalized to -actin intensities. Expression patterns as 
determined by qRT-PCR were similar to those observed in the 
microarray data (Supplementary Fig. S1). However, there were 
some discrepancies in TMEM140, CD34, and EGR1 between 
the results from microarray and qRT-PCR in both HMGB-1- 
treated and VEGF-treated samples. We, therefore, further 
performed qRT-PCR analysis of the three genes using GAPDH, 
another highly stable housekeeping gene, and compared the 
results with our microarray data normalized to GAPDH 
intensities, which allowed us to observe minimal discre-
pancies between the results from the microarray and qRT-PCR 
in all three genes (Supplementary Fig. S2A and S2B). Our 
microarray data were further validated at the protein level. We 
obtained commercially available antibodies against CCL2, 
PCDH12, CD34, and EGR1 and performed western blotting 
analysis with the same EC samples used for the qRT-PCR 
analysis. Western blotting analysis showed that the mRNA 
expressions of the four genes were highly proportional to their 
protein expressions, which validates our microarray data 
(Supplementary Fig. S2C and S2D).
HMGB-1 and VEGF induce characteristic activation of 
angiogenic pathways 
The number of genes upregulated by HMGB-1 or VEGF by 
more than 1.5-fold gradually increased in a time-dependent 
manner, with more genes upregulated by VEGF than HMGB-1 
at each time point. Using this list of upregulated genes at each 
time point, we performed gene enrichment and functional 
annotation analyses with DAVID. 
Most upregulated genes after 20 minutes of VEGF treatment 
belonged to well-documented VEGF-dependent angiogenic 
pathways, such as the MAP kinase, hypoxia, chemotaxis, cell 
migration, cell proliferation, apoptosis, angiogenesis, vasculo-
genesis, tumor necrosis factor (TNF) signaling, and transforming 
growth factor beta receptor (TGFBR) signaling pathways (3, 
18). Most of these pathways remained activated after 45 
minutes of VEGF treatment, at which point the unfolded 
protein response (UPR), cell adhesion, NF-B signaling, and 
cell differentiation pathways were newly activated. No 
significant changes in the activated pathways were found after 
2 hours of VEGF treatment except for the upregulation of some 
genes related to the canonical Wnt and Notch signaling 
pathways, which are also known to be involved in vessel 
branching. Similarly, no major changes in the activated 
pathways were found after 6 hours and 12 hours of VEGF 
treatment, but increased activation of UPR and new activation 
of the Rap1 signaling and PI3K-Akt signaling pathways were 
noted. UPR signaling has been recently highlighted due to its 
involvement in HIF1-mediated VEGF expression and angio-
genesis in cancers. These findings indicate that angiogenic 
pathways are concomitantly and strongly induced promptly 
after VEGF treatment and remain activated for an extended 
period. Overall, the TNF, TGFBR2, NF-B, and MAP kinase 
signaling pathways showed early activation after VEGF 
treatment, whereas the canonical Wnt, Notch, Rap1, and 
PI3K-Akt signaling pathways showed relatively late activation 
(Supplementary Table 1). 
At early time points (20 and 45 minutes after HMGB-1 
treatment), 28 genes were upregulated by HMGB-1, and these 
were related to inflammatory response, cell adhesion, trans-
cription, and signal transduction, which are pathways 
activated in the early process of HMGB-1 binding to its 
receptor. After 2 hours of HMGB-1 treatment, 49 genes were 
upregulated, and some of which belonged to angiogenic 
pathways such as cell proliferation and hypoxia. Our 
functional annotation analysis further showed that 85 and 182 
genes were upregulated 6 and 12 hours after HMGB-1 
treatment, respectively, and these were closely related to both 
direct and indirect angiogenic pathways, such as response to 
wounding, blood vessel development, cell proliferation, 
apoptosis, vasculogenesis, angiogenesis, and inflammatory 
response. These findings suggest that prolonged exposure to 
HMGB-1 initiates strong activation of direct angiogenic 
pathways including migration, proliferation, and sprouting in 
ECs, accompanying early activation of the inflammatory 
response, an indirect angiogenic pathway. Although HMGB-1 
and VEGF commonly induced EC activation and subsequent 
angiogenesis, HMGB-1-mediated activation of ECs was shown 
to be quite different from VEGF-mediated activation in terms of 
the order of pathway activation and the upregulated genes 
involved (Supplementary Table 1). 
HMGB-1 induces novel angiogenic and oncogenic genes
Integrative gene ontology analysis was performed using the 
245 genes upregulated more than 1.5-fold during at least one 
time point after HMGB-1 treatment (Fig. 2C). Of these, 99 
genes were upregulated by both HMGB-1 and VEGF treatment. 
Ontology analysis of the 146 genes specifically upregulated by 
HMGB-1 revealed no significant angiogenesis-relevant pathways, 
while the 99 genes upregulated by both HMGB-1 and VEGF 
were closely related to direct and indirect angiogenic 
pathways, such as response to wounding, inflammatory 
response, angiogenesis, cell chemotaxis, and cell proliferation. 
To analyze the time-dependent expression changes of each 
gene, we further selected the 83 genes upregulated more than 
1.5-fold during at least two time points (Fig. 2C). Importantly, 
expression of most genes (n = 62) started to increase after 6 
hours of HMGB-1 treatment and remained upregulated until 
12 hours of HMGB-1 treatment (Fig. 2D). Out of the 83 genes, 
59 were specifically upregulated by HMGB-1, and some of 
these genes were related to angiogenic pathways including 
inflammatory response, cell proliferation, epidermal growth 
factor receptor (EGFR) signaling, and cell–cell junction. 
Specifically, ABL2, AFAP1L2, APOL3, CEACAM1, CHST1, 
CLDN5, KIT, PLA2G4C, RHBDF2, TNFRSF21, GJA4, and 
VIPR1 are reported to play a role in physiological or 
pathological angiogenesis (Supplementary Table 2). We further 
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selected ABL2, CEACAM1, VIPR1, and KIT to demonstrate the 
angiogenic roles of the HMGB-1 specifically upregulated 
genes. Wound healing and tube formation assays were 
performed after HMGB-1 treatment when HMGB-1 specifically 
upregulated genes were inhibited by RNAi. Efficient 
downregulation of each gene was confirmed by qRT-PCR in 
ECs transfected with respective RNAi (Supplementary Fig. 
S3A). The wound healing assay showed that the wound 
healing process promoted by HMGB-1 treatment was 
significantly dysregulated by inhibition of ABL2, CEACAM1, 
and VIPR1 and most potently by inhibition of KIT 
(Supplementary Fig. S3B and S3C). The tube formation assay 
also showed a similar result in which HMGB-1 treated ECs 
barely formed capillary-like structures when HMGB-1 
specifically up-regulated genes were inhibited. Consistent with 
the wound healing assay results, inhibition of KIT most 
dramatically led to a reduction in capillary formation of ECs 
(Supplementary Fig. S3D and S3E).
Out of the 83 genes, the remaining 24 genes were upregu-
lated in both HMGB-1-treated and VEGF-treated ECs, and 
some of these were related to response to wounding, 
angiogenesis, cell adhesion, and cell chemotaxis, which were 
similarly identified in the analysis of the 99 genes upregulated 
by both HMGB-1 and VEGF during at least one time point. 
Specifically, CCL2, EPHB1, PCDH12, EGR1, and CD34 are 
involved in physiological or pathological angiogenesis 
(Supplementary Table 2). In contrast, 551 and 283 genes were 
found to be specifically upregulated (more than 1.5-fold) by 
VEGF during at least one time point and at least two time 
points, respectively. As expected, most of these genes were 
related to well- documented VEGF-induced direct and indirect 
angiogenic pathways, including cell migration, response to 
wounding, UPR signaling, PDGFR signaling, cell adhesion, 
cell proliferation, apoptosis, MAP kinase signaling, PI3K-Akt 
signaling, VEGFR signaling, Wnt signaling, TGFBR2 signaling, 
TNF signaling, Rap1 signaling, and NF-B signaling (Fig. 2C). 
DISCUSSION
Angiogenesis is the physiological or pathological proliferation 
of capillaries from pre-existing blood vessels. Importantly, 
pathological conditions such as tumor growth and metastasis 
accompany the dysregulation of angiogenesis, which can be 
induced by several major molecular mechanisms including 
hypoxia and abnormally activated VEGFR signaling (19). 
Although a significant fraction of patients with cancer respond 
to VEGF-targeted therapies, clinical use of VEGF blockers 
results in different outcomes according to cancer type (20, 21). 
Moreover, angiogenesis in patients with advanced cancer is 
regulated not only by VEGF but also by other proangiogenic 
molecules, making it difficult to block angiogenesis using 
VEGF inhibitors (18). HMGB-1, a cytokine broadly overex-
pressed in most cancers, is known to be a potent inducer of 
angiogenesis and has been studied as a target molecule for 
anti-angiogenic therapy (7, 11). Under both physiological and 
pathological conditions, HMGB-1 binds to RAGE, and the 
HMGB-1/RAGE axis activates the MAP kinase/NF-B and 
CDC42/Rac pathways, contributing to EC proliferation, 
migration, and sprouting (7). However, most of these findings 
were derived from unrelated in vitro experiments, and the 
molecular mechanism by which HMGB-1 activates ECs and 
subsequently induces angiogenesis remains unclear. 
In this study, we performed time-dependent gene expression 
analysis of ECs to characterize HMGB-1- or VEGF-mediated 
changes in the transcriptome. Ontology analysis showed that 
genes upregulated by VEGF mostly belonged to conventional 
VEGF/VEGFR axis-mediated pathways such as cell proliferation, 
migration, death, angiogenesis, and hypoxia. Most of these 
angiogenic pathways were activated promptly after VEGF 
treatment and showed increased activation over time. 
HMGB-1-induced angiogenic pathways mostly overlapped 
with those activated by VEGF, even though the upregulated 
genes in these common pathways differed. Moreover, 
angiogenic pathways began to be highly activated after 6 
hours of HMGB-1 treatment. These findings suggest that 
HMGB-1-induced angiogenesis might require a longer period 
of exposure than VEGF-induced angiogenesis and involve 
some HMGB-1-specific angiogenic factors. 
We found that 83 genes were upregulated by HMGB-1 
during at least two time points, and most of these were 
continuously upregulated from 6 to 12 hours after HMGB-1 
treatment. Out of these 83 genes, 24 were upregulated by both 
HMGB-1 and VEGF, and most of these were closely related to 
angiogenic pathways including response to wounding, angio-
genesis, cell adhesion, and cell chemotaxis, suggesting that 
HMGB-1 at least partially induces angiogenesis in a VEGF-like 
manner. Based on the known functions of these 24 genes, 13 
genes were related to physiological or tumor angiogenesis. 
Notably, four genes (CCL2, EGR1, EPHB1, and PCDH12) are 
reported to independently promote angiogenesis in vitro or in 
vivo. CCL2 accelerates cancer metastasis by promoting 
angiogenesis, and its expression is also regulated by the 
HMGB-1-mediated activation of TLR4 signaling (22, 23). EGR1 
is a well-known angiogenic factor whose expression is re-
portedly regulated by HMGB-1/RAGE signaling and VEGF/ 
VEGFR signaling (24, 25). In addition, EGR1 is reportedly 
involved in endothelial cell growth, tumor angiogenesis, and 
tumor growth and has even been considered as an anti- 
angiogenic therapeutic target (25). EPHB1, another well-known 
angiogenic factor, is expressed in the developing vasculature 
and promotes angiogenesis (26). PCDH12 is required for 
normal angiogenesis and is highly expressed in angiogenic ECs 
(27). We here report the relationships between HMGB-1 and 
the genes EPHB1 and PCDH12 for the first time. 
The characterization of the 59 genes that were specifically 
upregulated by HMGB-1 during at least two time points is 
crucial, as these genes explain HMGB-1-specific angiogenesis. 
We found that 12 genes were functionally related to 
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angiogenesis, and four (ABL2, CEACAM1, KIT, and VIPR1) are 
reported to directly induce in vitro and in vivo angiogenesis. 
ABL2, an oncogenic non-receptor tyrosine kinase, is reported 
to be critical for the survival and activation of ECs (28). 
CEACAM1, a cell adhesion protein, functions as an activator in 
both physiological and tumor angiogenesis by inducing blood 
vessel remodeling through EC differentiation (29). KIT is a 
well-known oncogenic receptor tyrosine kinase with reported 
involvement in physiological and tumor angiogenesis (30). 
VIPR1, a vasoactive intestinal peptide receptor, plays a major 
role in progression and angiogenesis in a number of cancers 
(31, 32). In our wound healing and tube formation assays, we 
demonstrated that inhibition of these four genes dramatically 
disturbed HMGB-1 mediated angiogenic features in ECs, 
which suggests that HMGB-1 specifically upregulated genes 
play critical roles in evoking angiogenic features in ECs. In this 
context, HMGB-1-mediated upregulation of these four genes 
could cause VEGF independent angiogenesis, which might 
explain drug resistance to anti-angiogenesis therapy based on 
VEGF inhibitors in cancer patients.
HMGB-1 induces the upregulation of HMGB-1-specific 
angiogenic factors, accompanying VEGF-like upregulation of 
some conventional angiogenic factors. This suggests that 
HMGB-1 can independently induce angiogenesis and also 
synergistically enhance VEGF-mediated angiogenesis. In future 
studies, the angiogenic genes induced by HMGB-1 should be 
further characterized to understand how they contribute to 
angiogenesis in physiological and tumor microenvironments 
and how to inhibit abnormal angiogenesis in various cancers.
MATERIALS AND METHODS
Cell culture and treatment 
Primary human umbilical vein endothelial cells (HUVECs) 
were isolated from human placental microvessels according to 
previous methods (33, 34) and maintained in M199 (GE 
Healthcare Life Sciences, Logan, UT, USA) supplemented with 
20% fetal bovine serum (FBS), 1% penicillin/streptomycin, 10 
g/ml bFGF (Sigma, St. Louis, MO, USA), and 2500 units/ml 
heparin (Sigma). This study was approved by the Institutional 
Review Board of Yonsei University College of Medicine 
(No.12-genebank-11). Written informed consent was obtained 
from all patients. HUVECs between the second and fifth 
passages were used. HUVECs were treated with recombinant 
HMGB-1 (ProSpec-Tany TechnoGene Ltd., Ness Ziona, Israel) 
at 1 g/ml and recombinant VEGF (ProSpec) at 50 ng/ml for 20 
minutes, 45 minutes, 2 hours, 6 hours, or 12 hours. 
Gene expression microarray 
For DNA microarray hybridization, RNA was extracted from 
HUVECs using TRIzol (Invitrogen Life Technologies, Carlsbad, 
CA, USA). RNA was pooled by mixing equal amounts of total 
RNA, and biotin-labeled cRNA targets were synthesized from 
1.5 g of total RNA. Double-stranded cDNA synthesis was 
performed using the IlluminaⓇ TotalPrep RNA Amplification 
Kit (Illumina, Inc., San Diego, CA, USA), while biotin- 
UTP-labeled antisense RNA was transcribed in vitro using the 
Ambion MEGAscript kit (Ambion Life Technologies, Carlsbad, 
CA, USA). All steps of the labeling procedure were performed 
according to the manufacturers’ protocols. Microarray experi-
ments were conducted on the HumanHT-12 v4 Sentrix 
Expression BeadChip (Illumina) containing 47,231 probes 
representing 31,332 annotated genes. 
Gene enrichment, functional annotation, and statistical 
analyses
Data are expressed as mean ± standard deviation (SD). P ＜ 
.05 was considered significant. Student’s t-tests were performed 
using SPSS for Windows (SPSS Inc., Chicago, IL, USA). DAVID 
software (Database for Annotation, Visualization and Integrated 
Discovery, v6.8; http://david.abcc.ncifcrf.gov) was used for 
pathway and gene ontology analysis.
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